Investors who purchased Encompass Health Corporation securities may be entitled to compensation due to allegations of misleading business information. A potential class action is being prepared to seek recovery of investor losses. To join, visit https://rosenlegal.com/submit-form/?case_id=44051 or call Phillip Kim, Esq. at 866-767-3653.
Investors who purchased Encompass Health Corporation (NYSE: EHC) securities may be eligible for compensation due to allegations of misleading business information. Rosen Law Firm, a global investor rights law firm, has announced an investigation into potential securities claims on behalf of Encompass Health shareholders. The firm is preparing a class action to recover investor losses, with no out-of-pocket fees or costs under a contingency fee arrangement.
The investigation stems from a New York Times article published on July 15, 2025, which highlighted potential safety issues and patient harm incidents at rehab hospitals operated by Encompass Health. The article stated that these facilities perform below average on two key safety measures tracked by Medicare. Following the publication, Encompass Health stock fell by 10.3% on the same day [1].
Rosen Law Firm encourages investors to select qualified counsel with a proven track record in securities class actions. The firm has achieved significant settlements, including the largest ever against a Chinese company and has been ranked in the top 4 annually since 2013. In 2019 alone, the firm secured over $438 million for investors [1].
To join the prospective class action, investors can visit https://rosenlegal.com/submit-form/?case_id=44051 or contact Phillip Kim, Esq., toll-free at 866-767-3653 or via email at case@rosenlegal.com.
References:
[1] https://www.marketscreener.com/news/rosen-leading-investor-counsel-encourages-encompass-health-corporation-investors-to-inquire-about-ce7c50ded18cf22d
[2] https://www.morningstar.com/news/pr-newswire/20250829dc62364/ehc-investors-have-opportunity-to-lead-encompass-health-corporation-securities-fraud-lawsuit
Comments
No comments yet